1) is a disease of which the etiology is unknown. The disease is characterized by the so-called positive and negative symptoms. Positive symptoms include hallucinations and paranoia. The most characteristic negative symptoms are social withdrawal and flattening of the personality. In addition, both cognitive as well as depressive symptoms and anxiety may occur.
The rationale behind the combination of a D 2 receptor antagonist and a 5-HT 1A receptor agonist is based on several preclinical data, supporting the hypothesis that selective 5-HT 1A receptor agonists are capable of preventing D 2 receptor antagonist induced EPS in animal models. The 5-HT 1A receptor agonist 8-hydroxy-2-(di-N-propylamino) tetralin (3) (8-(OH)-DPAT, Fig. 1 ) is capable of antagonizing haloperidol (1) induced catalepsy in rats and dystonia in non human primates, 5) and reduces the forelimb retraction time in the paw test. 6 ) Furthermore, 5-HT 1A receptor agonists are active in the forced swimming test (FST), a preclinical model predictive of antidepressant activity. 7) This report focusses on compounds of type (4) (Fig. 2 ) which share affinity for dopamine D 2 as well as serotonin 5-HT 1A receptors. Compound (4e) of this series possessed the desired profile (full dopamine D 2 receptor antagonism and full serotonin 5-HT 1A receptor agonism) and was selected as a clinical candidate.
In this paper we like to demonstrate that compounds (4) behave quite differently compared to our previously published 1) series of compounds (5) when examining their functional behavior on both dopamine D 2 and serotonin 5-HT 1A receptors.
Chemistry
The synthesis of compounds (4) is depicted in Chart 1. The compounds (4a-e) were prepared by reacting elto- prazine (6) and a biarylmethyl halide (7) in the presence of Et(i-Pr) 2 N and KI in acetonitrile at reflux temperature. Yields of 4a-e ranged from 38 to 83%. Some of the compounds (4) were converted into their mono-or di-HCl salts by treatment with HCl/EtOH. The intermediates (7a-e) were synthesized according to the procedures described in the references given in the experimental part. The syntheses of compounds (5) are described in the literature. 1, 8) In Table 1 the relevant compounds (4) and (5) are depicted.
Biological Evaluation and Discussion
The affinities of compounds (1-5) for dopamine D 2 and the serotonin 5-HT 1A receptors were measured using [ 3 H]-spiperone 10) and [ 3 H]-8-OH-DPAT respectively. 11) Both assays make use of rat receptors. In Fig. 1 , the K i values are given (calculated from at least three independent experiments) for compounds (1), (2) and (3). In Table 1 , the affinities of 4 and 5 expressed as K i values for both receptors are listed.
Within the series (4), replacement of a carbon atom by a nitrogen atom in the aromatic ring Ar1 was studied in order to improve pharmacokinetic properties. This had a dopamine D 2 receptor affinity lowering effect if the nitrogen atom was introduced on position Y 2 : affinity drops from 1.7 nM (4a) to 26 nM for compound (4b). The affinities for compounds (4c), (4d) and (4e) in which carbon to nitrogen replacement is on positions Y 4 , Y 6 and Y 5 respectively, remain almost unaltered. The presence of a fluorine atom in compounds (4c), (4d) and (4e) did not seem to play a crucial role for dopamine D 2 receptor affinity. Considering the serotonin 5-HT 1A receptor affinities in series (4), compounds (4b) and (4c), in contrast to (4d) and (4e), show a drop in affinity compared to (4a).
When series (4) are compared to series (5) it can be seen from Table 1 that series (5) compounds are slightly more potent on dopamine D 2 receptors than series (4) compounds, with the exception of compound (5a). This effect is most pronounced when comparing (4d) to (5d). Affinity for serotonin 5-HT 1A receptors in series (4) increases when comparing (5a) to (4a) and (5d) to (4d). Introduction of a nitrogen atom on position Y 4 is unfavourable for the serotonin 5-HT 1A receptor affinity in the case of compound (4c) as well as for compound (5c).
The compounds of series (4) were tested in in vivo models relevant for D 2 receptor antagonism-inhibition of the apomorphine-induced climbing behavior (CB) in mice 12) -, and for antipsychotic activity-the suppression of the conditioned avoidance response (CAR) in rats 13) -. To determine the 5-HT 1A receptor agonistic component in vivo, the compounds were tested for the occurrence of the so called lower lip retraction in rats (LLR). 14) The results are given in Table  2 .
Considering the in vivo profiles of series (4), compound (4b) and (4c) turned out to be not potent enough in the CB test and were not investigated further. Compounds (4d) and (4e) both show an attractive in vivo profile: they are potent in the CB test and about equipotent with regard to the CAR and LLR test, which may lead to equal expression of the desired D 2 -and 5-HT 1A mediated therapeutic actions at a given dose. Compound (4a) does show activity (p.o.) in the CB, CAR and LLR tests, but less potently than (4d) and (4e). After further preclinical profiling of the compounds (4d) and (4e), the latter was selected for further investigation. In order to establish the desired full dopamine D 2 receptor antagonism and full serotonin 5-HT 1A receptor agonism, some related compounds of series (4) and (5) were tested for their (ant)agonistic properties in vitro. This was accomplished by using CHO cells transfected with either the human dopamine D 2 receptor 15, 16) or the human serotonin 5-HT 1A receptor. 17) In this type of experiments receptor agonists decrease forskolin induced levels of the tritium labeled second messenger [ 3 H]-cAMP, giving the value of the intrinsic efficacy (e) of the compound studied. A ligand not decreasing the cAMP level, is an antagonist (eϭ0%), a compound bringing cAMP levels down to zero is a full agonist (eϭ100%). Partial agonists have e values between 0 and 100%. As can be seen from Table 3 , it turned out that independent of the arylpiperazine chosen, the 3-(4-fluorophenyl)-pyridyl-5-yl-methyl moiety induces full 5-HT 1A agonism ((4e) eϭ96% and (5e) eϭ96%). Furthermore, the benzodioxanyl piperazine moiety induces full D 2 antagonism, ((4a) eϭ9% and (4e) eϭ2%), independently of the biarylmethyl part of the molecule. These structural tools enable to design all four possible combinations of D 2 antagonism/partial agonism and 5HT 1A full agonism/partial agonism.
Compound (5a) that was previously selected for clinical development 1) shows partial agonism at both sites. Compound (4e) on the other hand displays full antagonism at dopamine D 2 receptors and full agonism at serotonin 5-HT 1A receptors and was therefore studied in more detail. Some calculated and measured physico-chemical properties that may be of relevance for pharmacokinetic behavior, are depicted in Table 4 .
Favorable absorption may be predicted on the basis of the low number of H-donor and H-acceptor sites and the relatively low molecular weight, logP 18, 19) and number of rotatable bonds. 20) The low polar surface area 21) (PSA) and a P-gp factor 22) around 1 indicate a favourable brain penetration. The measured high membrane passage further substantiates these expectations.
Indeed, a favorable bioavailability of 69% (dog) 23 ) and brain/plasma ratio of 4 (rat) 24) were measured. A more detailed publication describing the pharmacodynamic profile of SLV313 (4e) is in preparation.
Further clinical studies with (4e) may reveal if these preclinical properties also translate into a favorable therapeutic profile. 5 mmol) of 1-bromomethyl-3-phenyl benzene (7a) were suspended in 250 ml of dry acetonitrile. While stirring 10.5 ml (60 mmol) of diisopropylethylamine were added and the mixture was brought to reflux temperature for 16 h. After cooling to room temperature the reaction mixture was concentrated in vacuo, the residue was purified by flash column chromatography (SiO 2 , eluent CH 2 Cl 2 /MeOH 99/1). The product containing fraction was concentrated in vacuo, the residue taken up in methanol to which 2 eq of HCl (1 N HCl/MeOH) were added. Concentration in vacuo yielded 7.0 g (80%) of (4a) as the dihydrogenchloride salt. mp 223-225°C. 1 Values are based on 3 to 6 assays, measured at 1000 nM. When measuring (partial) agonism at even higher concentrations than 1000 nM, no higher percentages were found, indicating that the maximum degree of agonism is reached at 1000 nM. 
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a) Lipinski's "Rule of five", 18) log P was measured according to procedure described in ref. 19 . b) Any acyclic single bond connecting non-terminal, non-hydrogen atoms. 20) c) Calculated polar surface area. 21) d) P-Glycoprotein transport ratio, expressed as the ratio of the bottom to top transport and the top to bottom transport. 22) e) Membrane passage expressed as the mean percentage of compound transported. (7b) and 1.08 g (4.2 mmol) of (6) hydrochloride were suspended in 30 ml of acetonitrile after which 4.2 ml (25 mmol) of diisopropylethylamine were added and the mixture was brought to reflux temperature for 2 h. After cooling to room temperature the reaction mixture was concentrated in vacuo, to the residue water was added, after which extraction took place with CH 2 Cl 2 . The combined organic fractions were dried on Na 2 SO 4 . After removal of the drying agent by filtration and solvent by concentration in vacuo, the obtained residue was subjected to flash column chromatography (SiO 2 , eluent CH 2 Cl 2 /MeOH 97/3). The product containing fraction was concentrated in vacuo, the residue suspended in petroleum ether to which some diethyl ether was added. Stirring yielded 0.73 g (45%) of a white solid containing the free base of (4b) (6) together with 1.0 ml (5.7 mmol) of diisopropylethylamine were suspended/dissolved in 20 ml of dry acetonitrile. A little potassium iodide was added and the reaction mixture was stirred and brought to 80°C, under a nitrogen atmosphere. After 16 h the reaction mixture was cooled to room temperature and concentrated in vacuo. The residue was purified by column chromatography (SiO 2 , eluent: CH 2 Cl 2 /MeOH/NH 4 OH (25%) 92/7.5/0.5 v/v/v), yielding 0.48 g of a brown siruppy oil. To the latter 20 ml of tert-butyl methyl ether was added upon which some precipitate formed which was removed by filtration. The filtrate was treated with 5 ml 1 N HCl/EtOH and the precipitate which formed was collected by filtration yielding 1.3 g of a light brown solid, which was again purified by column chromatography (SiO 2 , eluent: CH 2 Cl 2 /MeOH/NH 4 OH (25%) 92/7.5/0.5 v/v/v), yielding a brown oil. The latter oil was dissolved in tert-butyl methyl ether and HCl (g) was led through the solution. The precipitate which formed was filtered, the residue washed with tert-butyl methyl ether and dried, yielding 0.36 g (32%) of the dihydrochloride of (4c (6), 0.50 g (1.94 mmol) of the hydrochloride of (7d), 0.80 ml (5.9 mmol) of triethylamine and 0.29 g (1.93 mmol) of sodium iodide. The resulting mixture was brought to reflux temperature for 3 h after which stirring was continued for 48 h at room temperature. To the reaction mixture some silicagel was added after which the mixture was concentrated in vacuo. The resulting powder was put on top of a flash chromatography column (SiO 2 , eluent: CH 2 Cl 2 /MeOH/NH 4 OH(25%) 92/7.5/0.5 v/v/v), and elution was started. The collected product containing fractions were concentrated in vacuo yielding 0.72 g of a brown sirup. The latter was dissolved in some diethyl ether and 2 eq of 1 N HCl/EtOH were added. The formed precipitate was isolated by filtration and dried, giving 0.77 g (83%) of the dihydrochloride of (4d). mp 233°C with decomposition. 1 Intermediates 1-Bromomethyl-3-phenylbenzene (7a): The synthesis of (7a) has been described in ref. 8 .
2-Chloromethyl-6-phenylpyridine (7b): The synthesis of (7b) and precursors has been described in refs. 26, 27 and 29.
4-Bromomethyl-2-(4-fluoro-phenyl)pyridine (7c): The synthesis of (7c) and precursors has been described in refs. 26 and 30.
2-Chloromethyl-4-(4-fluoro-phenyl)pyridine (7d): The synthesis of (7d) and precursors has been described in refs. 26 and 31.
3-Chloromethyl-5-(4-fluoro-phenyl)pyridine (7e): The synthesis of (7e) and precursors has been described in refs. 26, 28, 32 and 33.
